Professional
Added to YB: 2024-12-13
Pitch date: 2024-09-30
APLS [neutral]
Apellis Pharmaceuticals, Inc.
-12.09%
current return
Author Info
No bio for this author
Company Info
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Market Cap
$3.4B
Pitch Price
$28.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-16.23
P/E
-13.48
EV/Sales
4.86
Sector
Biotechnology
Category
N/A
PGIM Jennison Health Sciences Fund Portfolio Holding: Apellis Pharmaceuticals, Inc.
APLS trimmed position: Biotech with two drugs: pegcetacoplan for PNH & Syfovre for GA. Syfovre launch strong, but EU approval delay, Izervay competition, reimbursement issues & slower GA market growth led to position reduction. Safety concerns complicate marketing. Still bullish long-term but lowered expectations.
Read full article (1 min)